Wolverine Asset Management LLC Takes $10.52 Million Position in Drugs Made In America Acquisition II Corp. $DMII

Wolverine Asset Management LLC bought a new stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 1,062,773 shares of the company’s stock, valued at approximately $10,521,000.

Separately, Deltec Asset Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter valued at about $495,000.

Drugs Made In America Acquisition II Price Performance

NASDAQ DMII opened at $10.02 on Monday. Drugs Made In America Acquisition II Corp. has a 52 week low of $9.86 and a 52 week high of $10.02. The stock has a 50-day moving average price of $9.98.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on DMII shares. Weiss Ratings started coverage on shares of Drugs Made In America Acquisition II in a research note on Monday, March 2nd. They issued a “sell (e)” rating on the stock. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Drugs Made In America Acquisition II presently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.